Cargando…

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis

OBJECTIVE: Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and the flare rate on glucocorticoid tapering in patients with prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakai, Takehiro, Fukui, Sho, Ikeda, Yukihiko, Suda, Masei, Tamaki, Hiromichi, Okada, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163542/
https://www.ncbi.nlm.nih.gov/pubmed/35654482
http://dx.doi.org/10.1136/lupus-2022-000682
_version_ 1784719944313733120
author Nakai, Takehiro
Fukui, Sho
Ikeda, Yukihiko
Suda, Masei
Tamaki, Hiromichi
Okada, Masato
author_facet Nakai, Takehiro
Fukui, Sho
Ikeda, Yukihiko
Suda, Masei
Tamaki, Hiromichi
Okada, Masato
author_sort Nakai, Takehiro
collection PubMed
description OBJECTIVE: Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and the flare rate on glucocorticoid tapering in patients with prior severe organ involvement. METHODS: Data of patients with SLE with glucocorticoid tapering at our institution were retrospectively analysed. We divided the patients by the presence of prior severe organ involvement and compared flare rates after glucocorticoid discontinuation. Furthermore, we determined risk factors for flares after glucocorticoid discontinuation. RESULTS: In total, 309 patients with SLE were screened, 73 of whom met the inclusion criteria; 49 were classified as SLE with prior severe organ involvement. No significant differences were noted in the 52-week flare rate after glucocorticoid discontinuation between patients with and without prior severe organ involvement (16.7% vs 18.2%, p=1.0). Hypocomplementaemia, elevated anti-dsDNA antibody titres more than twice the upper limit of the laboratory reference range, positive anti-Smith/anti-ribonucleoprotein antibody, and use of any immunosuppressant on the day of glucocorticoid discontinuation were negatively associated with flare-free remission. CONCLUSIONS: Glucocorticoid discontinuation after gradual tapering can often be achieved in patients with SLE, even with prior severe organ involvement, especially when the disease is clinically and serologically stable.
format Online
Article
Text
id pubmed-9163542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91635422022-06-16 Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis Nakai, Takehiro Fukui, Sho Ikeda, Yukihiko Suda, Masei Tamaki, Hiromichi Okada, Masato Lupus Sci Med Epidemiology and Outcomes OBJECTIVE: Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and the flare rate on glucocorticoid tapering in patients with prior severe organ involvement. METHODS: Data of patients with SLE with glucocorticoid tapering at our institution were retrospectively analysed. We divided the patients by the presence of prior severe organ involvement and compared flare rates after glucocorticoid discontinuation. Furthermore, we determined risk factors for flares after glucocorticoid discontinuation. RESULTS: In total, 309 patients with SLE were screened, 73 of whom met the inclusion criteria; 49 were classified as SLE with prior severe organ involvement. No significant differences were noted in the 52-week flare rate after glucocorticoid discontinuation between patients with and without prior severe organ involvement (16.7% vs 18.2%, p=1.0). Hypocomplementaemia, elevated anti-dsDNA antibody titres more than twice the upper limit of the laboratory reference range, positive anti-Smith/anti-ribonucleoprotein antibody, and use of any immunosuppressant on the day of glucocorticoid discontinuation were negatively associated with flare-free remission. CONCLUSIONS: Glucocorticoid discontinuation after gradual tapering can often be achieved in patients with SLE, even with prior severe organ involvement, especially when the disease is clinically and serologically stable. BMJ Publishing Group 2022-06-01 /pmc/articles/PMC9163542/ /pubmed/35654482 http://dx.doi.org/10.1136/lupus-2022-000682 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology and Outcomes
Nakai, Takehiro
Fukui, Sho
Ikeda, Yukihiko
Suda, Masei
Tamaki, Hiromichi
Okada, Masato
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title_full Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title_fullStr Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title_full_unstemmed Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title_short Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
title_sort glucocorticoid discontinuation in patients with sle with prior severe organ involvement: a single-center retrospective analysis
topic Epidemiology and Outcomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163542/
https://www.ncbi.nlm.nih.gov/pubmed/35654482
http://dx.doi.org/10.1136/lupus-2022-000682
work_keys_str_mv AT nakaitakehiro glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis
AT fukuisho glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis
AT ikedayukihiko glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis
AT sudamasei glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis
AT tamakihiromichi glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis
AT okadamasato glucocorticoiddiscontinuationinpatientswithslewithpriorsevereorganinvolvementasinglecenterretrospectiveanalysis